This page shows the latest Calquence news and features for those working in and with pharma, biotech and healthcare.
Following AZ’s success with Calquence (acalabrutinib) – a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor – TNB-486 will further diversify the company’s haematology pipeline that have the potential
AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients. ... In a statement, AZ said that the results from the CALAVI trial do not impact the
Both cancer types are of particular interest for AZ as it plans to extend its oncology franchise beyond its approved therapies, which include PD-1 inhibitor Imfinzi (durvalumab), lymphoma treatment
AstraZeneca also received two positive opinions following the meeting, with a recommendation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia and a label extension of its PD-1 inhibitor Imfinzi (durvalumab)
Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in
Current treatment options for MCL include AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) and Johnson &Johnson/AbbVie’s BTK inhibitor Imbruvica (ibrutinib).
More from news
Approximately 6 fully matching, plus 18 partially matching documents found.
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...